title: Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
abstract: We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.
authors.forename: Alexander
authors.initials: A
authors.lastname: Claviez
authors.forename: Cornelia
authors.initials: C
authors.lastname: Eckert
authors.forename: Karl
authors.initials: K
authors.lastname: Seeger
authors.forename: André
authors.initials: A
authors.lastname: Schrauder
authors.forename: Martin
authors.initials: M
authors.lastname: Schrappe
authors.forename: Günter
authors.initials: G
authors.lastname: Henze
authors.forename: Arend
authors.initials: A
authors.lastname: von Stackelberg
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000628:therapy; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab